Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia by Evaluating Low-Sodium Oxybate Treatment) study Novel analysis of real-world Epidiolex…

The Calamos S&P 500® Structured Alt Protection ETF® – April (CPSP) is slated to launch April 1, 2025, with an estimated upside cap range of 7.21% – 7.50% over a one-year outcome period. The Calamos Russell 2000® Structured Alt Protection ETF® – April (CPRA) is slated to launch April,1…

Achieves Above Market Revenue Growth, Expands Diversification, Continues APAC Momentum AUBURN HILLS, Mich., March 19, 2025 /PRNewswire/ — Nexteer Automotive (HK 1316) today reported year end results for the period ended December 31, 2024, including record revenue of US$4.3 billion, an…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.